Clinical Trial

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Protocol Amendment History 5 changes
critical Trial completed 2026-07-02
notable Enrollment increased: 160 -> 182 participants 2026-07-02
notable Primary completion pushed: 2026-05 -> 2026-06 2026-05-12
minor Completion pushed: 2026-05 -> 2026-06 2026-05-12
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-10
Trial Details
NCT Number NCT06873516
Lead Sponsor Evommune, Inc.
Conditions Chronic Spontaneous Urticaria
Enrollment 182 participants
Start Date 2025-03-20
Primary Completion 2026-05-29 (estimated)
Study Completion 2026-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-01